Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD) Benefit/Risk Profile Improves - Oppenheimer

March 19, 2019 9:39 AM
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $85.00 price target on Gilead Sciences (NASDAQ: GILD) after examining the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments